OBJECTIVE: Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been reported as putative tumor markers because of their involvement in cancer invasion and metastasis. The aim of our study was to elucidate the possible role of MMP-2 and -9 as serum prognostic biomarker for breast cancer classification and correlate it with the clinicopathological variables. DESIGN AND METHODS: Our study consisted of 60 females with primary breast cancer, 40 cases of benign breast disease and 60 healthy female volunteers as controls. The serum MMP-2 and -9 levels were quantitatively measured by ELISA technique. RESULTS: A significantly raised MMP-2 and MMP-9 levels were observed in breast cancer patients. Significant rise in serum MMP-9 concentration was found in patients presenting with metastasis as well as in those cases who presented with a duration of less than 1year. ROC analyses depicted a serum cutoff value of 315ng/mL for MMP-9 to discriminate the breast cancer patients from the control group. CONCLUSION: Our results suggest that serum MMP-9 level is a better marker than serum MMP-2 in predicting the breast cancer development and progression.
OBJECTIVE: Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been reported as putative tumor markers because of their involvement in cancer invasion and metastasis. The aim of our study was to elucidate the possible role of MMP-2 and -9 as serum prognostic biomarker for breast cancer classification and correlate it with the clinicopathological variables. DESIGN AND METHODS: Our study consisted of 60 females with primary breast cancer, 40 cases of benign breast disease and 60 healthy female volunteers as controls. The serum MMP-2 and -9 levels were quantitatively measured by ELISA technique. RESULTS: A significantly raised MMP-2 and MMP-9 levels were observed in breast cancerpatients. Significant rise in serum MMP-9 concentration was found in patients presenting with metastasis as well as in those cases who presented with a duration of less than 1year. ROC analyses depicted a serum cutoff value of 315ng/mL for MMP-9 to discriminate the breast cancerpatients from the control group. CONCLUSION: Our results suggest that serum MMP-9 level is a better marker than serum MMP-2 in predicting the breast cancer development and progression.
Authors: William R Alley; Jacqueline A Vasseur; John A Goetz; Martin Svoboda; Benjamin F Mann; Daniela E Matei; Nancy Menning; Ahmed Hussein; Yehia Mechref; Milos V Novotny Journal: J Proteome Res Date: 2012-03-07 Impact factor: 4.466
Authors: Sarah A Aroner; Bernard A Rosner; Rulla M Tamimi; Shelley S Tworoger; Nadja Baur; Thomas O Joos; Susan E Hankinson Journal: Cancer Epidemiol Date: 2015-03-19 Impact factor: 2.984
Authors: Yan Zeng; Caiyun Liu; Bin Dong; Yuanyuan Li; Beihai Jiang; Ye Xu; Lin Meng; Jian Wu; Like Qu; Chengchao Shou Journal: Med Oncol Date: 2013-04-02 Impact factor: 3.064
Authors: Yeonju Kim; Nicholas J Ollberding; Yurii B Shvetsov; Adrian A Franke; Lynne R Wilkens; Gertraud Maskarinec; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Marc T Goodman Journal: Breast Cancer Res Treat Date: 2012-10-31 Impact factor: 4.872